1A02_HUMAN - dbPTM
1A02_HUMAN - PTM Information in dbPTM
Basic Information of Protein
UniProt ID 1A02_HUMAN
UniProt AC P01892
Protein Name HLA class I histocompatibility antigen, A-2 alpha chain
Gene Name HLA-A
Organism Homo sapiens (Human).
Sequence Length 365
Subcellular Localization Membrane
Single-pass type I membrane protein.
Protein Description Involved in the presentation of foreign antigens to the immune system..
Protein Sequence MAVMAPRTLVLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAVITGAVVAAVMWRRKSSDRKGGSYSQAASSDSAQGSDVSLTACKV
Overview of Protein Modification Sites with Functional and Structural Information
Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations Modification Substrate Peptides
&
Secondary Structure		 ASA (%) Reference Orthologous
Protein Cluster
110N-linked (GlcNAc)GTLRGYYNQSEAGSH
HHHHHHCCCCCCCCE		30.3419159218
135N6-methyllysineGSDWRFLRGYHQYAY
CCCCEEEEEEEEEEE		40.69115478757
145UbiquitinlysineHQYAYDGKDYIALKE
EEEEECCEEEEEECC		44.4521906983
21890473
151UbiquitinlysineGKDYIALKEDLRSWT
CEEEEEECCCCCCCC		39.9121906983
21890473
155N6-methyllysineIALKEDLRSWTAADM
EEECCCCCCCCCCCH		42.33115478751
168UbiquitinlysineDMAAQTTKHKWEAAH
CHHHHHHHHHHCCHH		46.7221906983
21890473
188 S-glutathionyl cysteineRAYLEGTCVEWLRRY
HHHHCCHHHHHHHHH		3.7222555962
200UbiquitinlysineRRYLENGKETLQRTD
HHHHCCCCCCCCCCC		60.1421906983
21890473
267N6-methyllysineAGDGTFQKWAAVVVP
CCCCCEEEEEEEEEC		34.3124623505
267UbiquitinlysineAGDGTFQKWAAVVVP
CCCCCEEEEEEEEEC		34.3121906983
21890473
292UbiquitinlysineVQHEGLPKPLTLRWE
EECCCCCCCEEEEEC		58.6721906983
21890473
340UbiquitinlysineRRKSSDRKGGSYSQA
EECCCCCCCCCCCCC		73.0321906983
21890473
344PhosphotyrosineSDRKGGSYSQAASSD
CCCCCCCCCCCCCCC		14.211956339
350PhosphoserineSYSQAASSDSAQGSD
CCCCCCCCCCCCCCE		30.7524275569
352PhosphoserineSQAASSDSAQGSDVS
CCCCCCCCCCCCEEE		25.1724275569
356PhosphoserineSSDSAQGSDVSLTAC
CCCCCCCCEEEECCC		23.8218088087
23186163
24275569
359PhosphoserineSAQGSDVSLTACKV-
CCCCCEEEECCCCC-		25.6223186163
24275569
364UbiquitinlysineDVSLTACKV------
EEEECCCCC------		48.8121906983
21890473
Disease-associated PTM Sites based on nsSNP

* Distance = the distance between SNP position and PTM sites.

Modified Location Modification Variant Position
(Distance <= 10) 		Residue Change SNP Related Disease Reference
110N-linked Glycosylation119 (9)V ⇒ Lrs1071743--
135Methylation131 (4)W ⇒ Grs1136702--
155Methylation162 (7)M ⇒ Krs41549316--
168Ubiquitination173 (5)A ⇒ Trs1059526--
168Ubiquitination162 (6)M ⇒ Krs41549316--
168Ubiquitination176 (8)V ⇒ Ers9256983Pneumonia: susceptibility to pneumonia measurement28928442
188Glutathionylation191 (3)W ⇒ Grs3098019--
188Glutathionylation190 (2)E ⇒ Drs879577815--
188Glutathionylation180 (8)L ⇒ Wrs9260156--
200Ubiquitination191 (9)W ⇒ Grs3098019--
200Ubiquitination190 (10)E ⇒ Drs879577815--
267Methylation260 (7)A ⇒ Ers41540417--
267Ubiquitination260 (7)A ⇒ Ers41540417--
Protein-Protein Interaction
Interacting Protein Gene Name Interaction Type PPI Reference Domain-Domain Interactions
UGGG1_HUMANUGGT1physical
17353931
CD8A_HUMANCD8Aphysical
9177355
CD8A_HUMANCD8Aphysical
10809759
COPB_HUMANCOPB1physical
11884415
COPG1_HUMANCOPG1physical
11884415
TPSN_HUMANTAPBPphysical
11884415
TAP1_HUMANTAP1physical
11884415
SYVN1_HUMANSYVN1physical
21245296
UB2J1_HUMANUBE2J1physical
21245296
DERL1_HUMANDERL1physical
21245296
PSMD2_HUMANPSMD2physical
21245296
MAGA4_HUMANMAGEA4physical
21815906
BAP31_HUMANBCAP31physical
17056546
B2MG_HUMANB2Mphysical
8805302
STAT3_HUMANSTAT3physical
21988832
GNAS3_HUMANGNASphysical
9914489
GNAS2_HUMANGNASphysical
9914489
ALEX_HUMANGNASphysical
9914489
GNAS1_HUMANGNASphysical
9914489
BAG6_HUMANBAG6physical
21636303
MEOX2_HUMANMEOX2physical
24722188
Drug and Disease Associations
Kegg Disease
OMIM Disease
There are no disease associations of PTM sites.
Kegg Drug
DrugBank
There are no disease associations of PTM sites.
Related Literatures of Post-Translational Modification
N-linked Glycosylation
ReferencePubMed
"Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry.";
Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
J. Proteome Res. 8:651-661(2009).
Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110, AND MASSSPECTROMETRY.
Phosphorylation
ReferencePubMed
"Phosphoproteome of resting human platelets.";
Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.;
J. Proteome Res. 7:526-534(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, ANDMASS SPECTROMETRY.
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, ANDMASS SPECTROMETRY.

TOP
© 2018 Arieh Warshel Institute of Computational Biology, CUHK(SZ) | Designed by : BiOmics Laboratory